why choose us

First received: October 26, 2022

Clinical Trial: Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Study Status: Completed

Recruit Status: RECRUITING

Condition: End-stage Kidney Disease

Study Type: INTERVENTIONAL


Official Title: Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Brief Summary: The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients.In the recent years, empagliflozin has become a major tool to prevent heart failure hospitalization and to reduce the risk for cardiovascular death in diabetic and non-diabetic patients.Although patients with severe chronic kidney disease and ESKD have very high risk of heart failure and cardiovascular death,…

Read more